

Date 15th February 2011

Dr Carole Longson
Director
Health Technology Evaluation Centre
National Institute for Health and Clinical Excellence
Level 1A, City Tower
Piccadilly Plaza
Manchester
M1 6NA



Quarry House
Quarry Hill
Leeds
LS2 7UE

Tel: [REDACTED]

Dear Carole

Patient Access Scheme – Simponi (golimumab) in the treatment of psoriatic arthritis, rheumatoid arthritis and ankylosing spondylitis

I am writing to confirm the Department of Health's position on the Patient Access Scheme (PAS) arrangements that have been proposed by Merck Sharp & Dohme for Simponi (golimumab) in the treatment of psoriatic arthritis, rheumatoid arthritis and ankylosing spondylitis.

The Department is content for NICE to consider the PAS proposed by Merck Sharp & Dohme.

Yours sincerely

[REDACTED]